Zumutor Biologics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.zumutor.com
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung CancerEsophageal CancerProstate CancerUrothelial CarcinomaTriple Negative Breast CancerPancreas AdenocarcinomaBiliary Tract CancerHigh Grade Ovarian Serous AdenocarcinomaDiffuse Large B Cell LymphomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Zumutor Biologics Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT06451497
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath